Abstract
Objective To compare alternative methods of adjusting self-reported knowledge of HIV-positive status and antiretroviral (ARV) therapy use based on undetectable viral load (UVL) and ARV detection in blood.
Design Post hoc analysis of nationally-representative household survey to compare alternative biomarker-based adjustments to population HIV indicators.
Methods We reclassified HIV-positive participants aged 15–64 years in the 2012 Kenya AIDS Indicator Survey (KAIS) that were unaware of their HIV-positive status by self-report as aware and on antiretroviral treatment if either ARVs were detected or viral load was undetectable (<550 copies/mL) on dried blood spots. We compared self-report to adjustments for ARVs measurement, UVL, or both.
Results Treatment coverage among all HIV-positive respondents increased from 31.8% for self-report to 42.5% [95% confidence interval (CI) 37.4–47.8] based on ARV detection alone, to 42.8% (95% CI 37.9–47.8) when ARV-adjusted, 46.2% (95% CI 41.3–51.1) when UVL-adjusted and 48.8% (95% CI 43.9–53.8) when adjusted for either ARV or UVL. Awareness of positive status increased from 46.9% for self-report to 56.2% (95% CI 50.7– 61.6) when ARV-adjusted, 57.5% (95% CI 51.9–63.0) when UVL-adjusted, and 59.8% (95% CI 54.2–65.1) when adjusted for either ARV or UVL.
Conclusions Undetectable viral load, which is routinely measured in surveys, may be a useful adjunct or alternative to ARV detection for adjusting survey estimates of knowledge of HIV status and antiretroviral treatment coverage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The 2012 Kenya AIDS Indicator Survey has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of #PS001805, GH000069, and PS001814. The survey was also funded in part by support from the Global Fund, World Bank, and the Joint United Nations Programme on HIV/AIDS.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of authors: PWY: pyoung1{at}cdc.gov EZG: ebz0{at}cdc.gov JW: jwamicwe{at}yahoo.co.uk IM: irenemukui5{at}gmail.com AAK: bwd2{at}cdc.gov AW: ivq3{at}cdc.gov CZ: cbz2{at}cdc.gov MEK: M.E.E.Kretzschmar{at}umcutrecht.nl KDC: kmd2{at}cdc.gov
Conflicts of interest and source of funding: The 2012 Kenya AIDS Indicator Survey has been supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of #PS001805, GH000069, and PS001814. The survey was also funded in part by support from the Global Fund, World Bank, and the Joint United Nations Programme on HIV/AIDS.
A portion of this analysis has been presented as a poster at the 2019 International AIDS Society (IAS) conference (http://programme.ias2019.org/Abstract/Abstract/4626).
Disclaimer: The findings and conclusions in this manuscript are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention and other funding institutions.
The authors declare no conflicts of interest.
Data Availability
Data for KAIS 2012 are available upon request from NASCOP by emailing head@nascop.or.ke, or from the Kenya National Bureau of Statistics by requesting at http://statistics.knbs.or.ke/nada/index.php
